Oncodesign Precision Medicine: OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-front Net income almost at break-even

Related Keywords

Arthur Rouill ,Jan Hoflack ,Karine Lignel ,Philippe Genne ,Mathilde Bohin Alban Dufumier ,Research Tax Credit ,Oncodesign Services ,Transition Service Agreement ,Precision Medicine ,Chief Executive Officer ,Oncodesign Biotechnology ,Euronext Growth ,Artificial Intelligence ,Monday April ,Ordinary General Meeting ,Oncodesign Precision Medicine ,Bohin Alban Dufumier ,Oncodesign ,Precision ,Medicine ,Nnounces ,022 ,Nnual ,Results ,Rovides ,Update ,Linical ,Developments ,